Gentian Diagnostics ASA — Cyborg Score 7/10

Strategic Profile

Gentian's portfolio and pipeline of diagnostic reagents span areas of kidney disease, cardiac disease, inflammation, infection and veterinary medicine. The company's PETIA technology enables 3-10x higher throughput than traditional immunoassay platforms, significantly improving laboratory productivity and cost-efficiency. Full year 2025 sales of NOK 176.5 million were up 16% (17% organic growth) vs 2024.

Cyborg Score Rationale

EBITDA increased 40% to NOK 34.6 million in 2025 vs NOK 24.7 million in 2024. Cystatin C sales increased 32% for full year 2025 versus 2024, driven by strong performance in the US. Recent product development challenges with NT-proBNP assay require monitoring.

Top Insights

• Record sales of NOK 46.6 million in 4Q25, up 9% vs 4Q24 (12% organic growth)
• Gross margin improved to 56% in 2025 versus 54% in 2024
• Exclusive partnership with top global diagnostics company announced; board proposes NOK 0.60 per share dividend based on solid cash position
• NT-proBNP assay development delayed due to reliability issues in lower measurement range; revised timelines expected Q2 2026

Named Competitors

• Clinical Chemistry Immunoassays — Large-cap diagnostics competitors offering comprehensive IVD solutions
• Turbidimetric Immunoassays — Direct competitors in particle-enhanced turbidimetric immunoassay space

Recent Developments

• (February 2026) Record 4Q25 sales and 40% EBITDA growth; NT-proBNP assay development update with revised timelines
• (February 2026) Exclusive global partnership announced for new assay on world's most widely used clinical chemistry analyzer
• (2025) Full year revenues reached NOK 176.5M (+16%); Cystatin C sales grew 32% year-over-year

Open the full interactive Gentian Diagnostics ASA report

Strategic research, analyst-debate audio, full Cyborg Score breakdown across 11 dimensions, and saved-company audio playlists.